Cargando…
TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis
Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress,...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464900/ https://www.ncbi.nlm.nih.gov/pubmed/28430599 http://dx.doi.org/10.18632/oncotarget.16895 |
_version_ | 1783242859358453760 |
---|---|
author | Guan, Shan Lu, Jiaxiong Zhao, Yanling Woodfield, Sarah E. Zhang, Huiyuan Xu, Xin Yu, Yang Zhao, Jing Bieerkehazhi, Shayahati Liang, Haoqian Yang, Jianhua Zhang, Fuchun Sun, Surong |
author_facet | Guan, Shan Lu, Jiaxiong Zhao, Yanling Woodfield, Sarah E. Zhang, Huiyuan Xu, Xin Yu, Yang Zhao, Jing Bieerkehazhi, Shayahati Liang, Haoqian Yang, Jianhua Zhang, Fuchun Sun, Surong |
author_sort | Guan, Shan |
collection | PubMed |
description | Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival. Herein, we examined whether TAK1 inhibition is a potential therapeutic strategy for treating cervical cancer. We found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of Dox in a panel of cervical cancer cell lines. Treatment with 5Z-7-oxozeaenol hindered Dox-induced NF-κB activation and promoted Dox-induced apoptosis in cervical cancer cells. Moreover, 5Z-7-oxozeaenol showed similar effects in both positive and negative human papillomavirus-infected cervical cancer cells. Taken together, our results provide evidence that TAK1 inhibition significantly sensitizes cervical cancer cells to chemotherapy-induced cell death and supports the use of TAK1 inhibitor with current chemotherapies in the clinic for patients with refractory cervical cancer. |
format | Online Article Text |
id | pubmed-5464900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54649002017-06-21 TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis Guan, Shan Lu, Jiaxiong Zhao, Yanling Woodfield, Sarah E. Zhang, Huiyuan Xu, Xin Yu, Yang Zhao, Jing Bieerkehazhi, Shayahati Liang, Haoqian Yang, Jianhua Zhang, Fuchun Sun, Surong Oncotarget Research Paper Aberrant activation of nuclear factor-κB (NF-κB) allows cancer cells to escape chemotherapy-induced cell death and acts as one of the major mechanisms of acquired chemoresistance in cervical cancer. TAK1, a crucial mediator that upregulates NF-κB activation in response to cellular genotoxic stress, is required for tumor cell viability and survival. Herein, we examined whether TAK1 inhibition is a potential therapeutic strategy for treating cervical cancer. We found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of Dox in a panel of cervical cancer cell lines. Treatment with 5Z-7-oxozeaenol hindered Dox-induced NF-κB activation and promoted Dox-induced apoptosis in cervical cancer cells. Moreover, 5Z-7-oxozeaenol showed similar effects in both positive and negative human papillomavirus-infected cervical cancer cells. Taken together, our results provide evidence that TAK1 inhibition significantly sensitizes cervical cancer cells to chemotherapy-induced cell death and supports the use of TAK1 inhibitor with current chemotherapies in the clinic for patients with refractory cervical cancer. Impact Journals LLC 2017-04-06 /pmc/articles/PMC5464900/ /pubmed/28430599 http://dx.doi.org/10.18632/oncotarget.16895 Text en Copyright: © 2017 Guan et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Guan, Shan Lu, Jiaxiong Zhao, Yanling Woodfield, Sarah E. Zhang, Huiyuan Xu, Xin Yu, Yang Zhao, Jing Bieerkehazhi, Shayahati Liang, Haoqian Yang, Jianhua Zhang, Fuchun Sun, Surong TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title | TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title_full | TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title_fullStr | TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title_full_unstemmed | TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title_short | TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
title_sort | tak1 inhibitor 5z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464900/ https://www.ncbi.nlm.nih.gov/pubmed/28430599 http://dx.doi.org/10.18632/oncotarget.16895 |
work_keys_str_mv | AT guanshan tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT lujiaxiong tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT zhaoyanling tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT woodfieldsarahe tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT zhanghuiyuan tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT xuxin tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT yuyang tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT zhaojing tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT bieerkehazhishayahati tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT lianghaoqian tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT yangjianhua tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT zhangfuchun tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis AT sunsurong tak1inhibitor5z7oxozeaenolsensitizescervicalcancertodoxorubicininducedapoptosis |